Lunan Liu

1 month ago | pubs.rsc.org | Lunan Liu |Ruiqi Chen |Yujing Song |Huishu Wang

Cancer-on-a-Chip for Precision Cancer Medicine Many cancer therapies fail in clinical trials despite showing potent efficacy in preclinical studies. One of the key reasons is the adopted preclinical models cannot recapitulate the complex tumor microenvironment (TME) and reflect the heterogeneity and patient specificity in human cancer.